نتائج البحث - "Caroline Robert"

1

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology

المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test

2

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials

المصدر: JAMA Oncol

مصطلحات موضوعية: Oncology, Male, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, Medizin, Subgroup analysis, Pembrolizumab, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Double-Blind Method, Internal medicine, Medicine, Humans, 030212 general & internal medicine, neoplasms, Melanoma, Protein Kinase Inhibitors, Survival analysis, Original Investigation, Aged, Mitogen-Activated Protein Kinase Kinases, business.industry, MEK inhibitor, Middle Aged, medicine.disease, Survival Analysis, Clinical trial, Treatment Outcome, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Mutation, Population study, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a942c45d9a0d560a1e0582292a5fe85Test
https://europepmc.org/articles/PMC7366279Test/

3

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma

المؤلفون: Jonathan Cebon, Neil Steven, Mark R. Middleton, Darcy A. Hille, Erika Richtig, Céleste Lebbé, Nageatte Ibrahim, Euan Walpole, Caroline Robert, Giuseppe Masucci, Wei Zhou, Wilson H. Miller, Teresa M. Petrella

المصدر: European Journal of Cancer. 86:115-124

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e890ea1bf10f65d9c5dbe680fbd78ba4Test
https://doi.org/10.1016/j.ejca.2017.08.032Test

4

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 20
Clinical Cancer Research
Clinical Cancer Research, 24(20), 4960–4967